ScholarIQanswers from OpenAlex & ORCID
Emilio Bria
ResearcherPublications, citations & collaboration network
Emilio Bria is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Emilio Bria have?
ScholarIQindexed works
Emilio Bria has 820 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Emilio Bria have?
ScholarIQcitation count
Emilio Bria has 16,178 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Emilio Bria?
ScholarIQh-index
Emilio Bria has an h-index of 62 in OpenAlex.
What is the i10-index of Emilio Bria?
ScholarIQi10-index
Emilio Bria has an i10-index of 280 in OpenAlex.
What is the ORCID of Emilio Bria?
ScholarIQorcid
The ORCID for Emilio Bria is on the source record.
What is the OpenAlex record for Emilio Bria?
ScholarIQopenalex
The OpenAlex for Emilio Bria is on the source record.
What are the most-cited papers on Emilio Bria?
ScholarIQmost cited works
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, J. Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Corentin Lefebvre, Rémi Veillon, Virginie Westeel, Serge Koscielny, Stéphane Champiat, Charles Ferté, David Planchard, Jordi Remón, Marie‐Eve Boucher, Anas Gazzah, Julien Adam, Emilio Bria, Giampaolo Tortora, Jean‐Charles Soria, Benjamin Besse, Caroline Caramella
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang, Annalisa Trama, Valter Torri, Francesco Agustoni, Javier Baena, Giuseppe Luigi Banna, Rossana Berardi, Anna Bettini, Emilio Bria, Matteo Brighenti, Jacques Cadranel, Alessandro De Toma, Claudio Chini, Alessio Cortellini, Enriqueta Felip, Giovanna Finocchiaro, Pilar Garrido, Carlo Genova, Raffaele Giusti, Vanesa Gregorc, Francesco Grossi, Federica Grosso, Salvatore Intagliata, Nicla La Verde, Stephen V. Liu, Julien Mazières, Edoardo Mercadante, Olivier Michielin, Gabriele Minuti, Denis Moro‐Sibilot, Giulia Pasello, Antonio Passaro, Vieri Scotti, Piergiorgio Solli, Elisa Maria Stroppa, Marcello Tiseo, Giuseppe Viscardi, Luca Voltolini, Yi‐Long Wu, Silvia Zai, Véra Pancaldi, Anne‐Marie C. Dingemans, Jan P. van Meerbeeck, Fabrice Barlési, Heather A. Wakelee, Solange Peters, Leora Horn
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Alessandro Leonetti, Diego Cortinovis, Joachim G.J.V. Aerts, Giorgia Guaitoli, Fausto Barbieri, Raffaele Giusti, Miriam Grazia Ferrara, Emilio Bria, Ettore D’Argento, Francesco Grossi, Erika Rijavec, Annalisa Guida, Rossana Berardi, Mariangela Torniai, Vincenzo Sforza, Carlo Genova, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe Luigi Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J. Pinato
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, Fabiana Letizia Cecere, Sara Pilotto, Vieri Scotti, Sabrina Rossi, Alessandro Del Conte, Emanuele Vita, Chiara Bennati, Andrea Ardizzoni, Giulio Cerea, Maria Rita Migliorino, Elisa Sala, Andrea Camerini, Alessandra Bearz, Elisa De Carlo, Francesca Zanelli, Giorgia Guaitoli, Marina Chiara Garassino, Lucia Pia Ciccone, Giulia Sartori, Luca Toschi, Filippo Gustavo Dall’Olio, Lorenza Landi, Elio Gregory Pizzutilo, Gabriele Bartoli, Cinzia Baldessari, Silvia Novello, Emilio Bria, Diego Cortinovis, Giulio Rossi, Antônio Rossi, Giuseppe Luigi Banna, Roberta Camisa, Massimo Di Maïo, Marcello Tiseo